Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE— The Diabetes Control and Complications Trial (Diabetes 44:968–983, 1995) presented statistical models suggesting that subjects with similar A1C levels had a higher risk of retinopathy progression in the conventional treatment group than in the intensive treatment group. That analysis has been cited to support the hypothesis that specific patterns of glucose variation, in particular postprandial hyperglycemia, contribute uniquely to an increased risk of microvascular complications above and beyond that explained by the A1C level. RESEARCH DESIGN AND METHODS— We performed statistical evaluations of these models and additional analyses to assess whether the original analyses were flawed. RESULTS— Statistically, we show that the original results are an artifact of the assumptions of the statistical model used. Additional analyses show that virtually all (96%) of the beneficial effect of intensive versus conventional therapy on progression of retinopathy is explained by the reductions in the mean A1C levels, similarly for other outcomes. Furthermore, subjects within the intensive and conventional treatment groups with similar A1C levels over time have similar risks of retinopathy progression, especially after adjusting for factors in which they differ. CONCLUSIONS— A1C explains virtually all of the difference in risk of complications between the intensive and conventional groups, and a given A1C level has similar effects within the two treatment groups. While other components of hyperglycemia, such as glucose variation, may contribute to the risk of complications, such factors can only explain a small part of the differences in risk between intensive and conventional therapy over time.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38014-2 · Cited by 814
Diabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Glycemic Variability: A Hemoglobin A1c–Independent Risk Factor for Diabetic Complications
Brownlee, M., & Hirsch, I. B. (2006) · JAMA · doi:10.1001/jama.295.14.1707 · Cited by 482
The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2006) · Diabetes Care · doi:10.2337/dc06-0293 · Cited by 377
Biostatistical methods : the assessment of relative risks
Lachin, J. M. (2000) · Cited by 272
Self-citation
Cited by
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Self-citationContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Young-Hyman, D., de Groot, M., Hill-Briggs, F., Gonzalez, J. S., Hood, K., & Peyrot, M. (2016) · Diabetes Care · doi:10.2337/dc16-2053 · Cited by 1,072
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Role of Inflammation in Diabetic Retinopathy
Rübsam, A., Parikh, S., & Fort, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040942 · Cited by 750
Screening for diabetic retinopathy: new perspectives and challenges
Vujosevic, S., Aldington, S. J., Silva, P., Hernández, C., Scanlon, P., Peto, T., & Simó, R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30411-5 · Cited by 671
DiMeglio, L. A., Acerini, C. L., Codner, E., Craig, M. E., Hofer, S. E., Pillay, K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12737 · Cited by 604
Glycemic Variability: How Do We Measure It and Why Is It Important?
Suh, S., & Kim, J. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.273 · Cited by 439
“The role of GV in the development of microvascular complications was initially suggested by the analysis of the diabetes control and complications trial (DCCT) data [37], which showed that increased HbA1c explained only 11% of the variation in the risk of retinopathy, meaning that factors independent of HbA1c must pre…”
MethodA1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2008) · Diabetes Care · doi:10.2337/dc08-0864 · Cited by 420
“A more recent reanalysis of the A1C data by the DCCT group has shown that the original differences between treatment groups was probably an artifact of model assumptions originally used and that no discrepancies in microvascular risk at the same A1C actually existed (10).”
MethodGlucose Variability; Does It Matter?
Siegelaar, S. E., Holleman, F., Hoekstra, J. B. L., & DeVries, J. H. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0021 · Cited by 409
Balaratnasingam, C., Inoue, M., Ahn, S., McCann, J., Dhrami-Gavazi, E., Yannuzzi, L. A., & Freund, K. B. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.07.008 · Cited by 367
Hill, N. R., Oliver, N. S., Choudhary, P., Levy, J. C., Hindmarsh, P., & Matthews, D. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0247 · Cited by 362
Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond
Hammes, H.-P. (2018) · Diabetologia · doi:10.1007/s00125-017-4435-8 · Cited by 357
“HbA1c only accounted for up to 11% of the entire risk for complications and concluded that most of the variation in risk was explained by factors not imaged by glycaemia [47].”
BackgroundAssociation between adherence and glycemic control in pediatric type 1 diabetes: a meta-analysis
Hood, K. K., Peterson, C. M., Rohan, J. M., & Drotar, D. (2009) · Pediatrics · doi:10.1542/peds.2009-0207 · Cited by 347
Assessment and monitoring of glycemic control in children and adolescents with diabetes
Rewers, M., Pihoker, C., Donaghue, K., Hanas, R., Swift, P., & Klingensmith, G. J. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00582.x · Cited by 342
Ziemer, D. C., Kolm, P., Weintraub, W. S., Vaccarino, V., Rhee, M. K., Twombly, J. G., Narayan, K. M. V., Koch, D. D., & Phillips, L. S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-12-201006150-00004 · Cited by 326
Continuous glucose monitoring: A review of the technology and clinical use
Klonoff, D. C., Ahn, D., & Drincic, A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.005 · Cited by 320
Assessment and monitoring of glycemic control in children and adolescents with diabetes
Rewers, M. J., Pillay, K., de Beaufort, C., Craig, M. E., Hanas, R., Acerini, C. L., & Maahs, D. M. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12190 · Cited by 316
Sun, Z., Tang, F., Wong, R., Lok, J., Szeto, S. K. H., Chan, J. C. K., Chan, C. K. M., Tham, C. C., Ng, D. S., & Cheung, C. Y. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.016 · Cited by 307
Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences
Stehouwer, C. D. A. (2018) · Diabetes · doi:10.2337/dbi17-0044 · Cited by 306
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., & Siebenhofer, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009122.pub2 · Cited by 299
Yapanis, M., James, S., Craig, M. E., O’Neal, D., & Ekinci, E. I. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac034 · Cited by 291
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s004 · Cited by 285
Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does!
Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc14-2898 · Cited by 282
Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
Nathan, D. M., Bayless, M., Cleary, P., Genuth, S., Gubitosi-Klug, R., Lachin, J. M., Lorenzi, G., Zinman, B., & for the DCCT/EDIC Research Group (2013) · Diabetes · doi:10.2337/db13-1093 · Cited by 272
“96% of the statistical difference between the treatment groups in risk of retinopathy onset or progression and 98 and 92% for nephropathy and neuropathy, respectively (22).”
BackgroundSelf-citationSu, G., Mi, S., Tao, H., Li, Z., Yang, H., Zheng, H., Zhou, Y., & Ma, C. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-19 · Cited by 257
Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes
Kovatchev, B., & Cobelli, C. (2016) · Diabetes Care · doi:10.2337/dc15-2035 · Cited by 255
Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control
Duca, L. M., Wang, B., Rewers, M., & Rewers, A. (2017) · Diabetes Care · doi:10.2337/dc17-0558 · Cited by 236
Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
Cryer, P. E. (2014) · Diabetes · doi:10.2337/db14-0059 · Cited by 236
“0% (53 mmol/mol) is not achievable safely, there is demonstrable microvascular benefit from reducing A1C from high to lower, albeit still above ideal, levels (71).”
BackgroundDiabetic Retinopathy in the Context of Patients with Diabetes
Simó-Servat, O., Hernández, C., & Simó, R. (2019) · Ophthalmic Research · doi:10.1159/000499541 · Cited by 233
Protective Factors and the Pathogenesis of Complications in Diabetes
Yu, M. G., Gordin, D., Fu, J., Park, K., Li, Q., & King, G. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad030 · Cited by 228
Tobias, D. K., Merino, J., Ahmad, A., Aiken, C., Benham, J. L., Bodhini, D., Clark, A. L., Colclough, K., Corcoy, R., Cromer, S. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02502-5 · Cited by 217
Service, F. J. (2013) · Diabetes · doi:10.2337/db12-1396 · Cited by 221
“Analogous to the vital role played by HbA1c in testing the “glucose hypothesis” is the need to establish an accurate and biologically relevant modality to test the “glycemic variability hypothesis.””
BackgroundInfluentialElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 222
Nathan, D. M., McGee, P., Steffes, M. W., Lachin, J. M., & the DCCT/EDIC Research Group (2014) · Diabetes · doi:10.2337/db13-0782 · Cited by 214
Self-citationSmith-Palmer, J., Brändle, M., Trevisan, R., Orsini Federici, M., Liabat, S., & Valentine, W. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.06.007 · Cited by 212
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Cusi, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 205
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s004 · Cited by 207
Lachin, J. M., Orchard, T. J., Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2116 · Cited by 206
Self-citationHypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
Saisho, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018381 · Cited by 195
“However, the DCCT investigators recently reanalyzed the data and denied their previous conclusion [23].”
BackgroundDiabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies
Whitehead, M., Wickremasinghe, S., Osborne, A., Van Wijngaarden, P., & Martin, K. R. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1545836 · Cited by 198
Stem, M., & Gardner, T. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990027 · Cited by 192
Lachin, J. M., Bebu, I., Bergenstal, R. M., Pop-Busui, R., Service, F. J., Zinman, B., Nathan, D. M., & for the DCCT/EDIC Research Group (2017) · Diabetes Care · doi:10.2337/dc16-2426 · Cited by 186
Self-citationBeyond Hemoglobin A1c—Need for Additional Markers of Risk for Diabetic Microvascular Complications
Hirsch, I. B. (2010) · JAMA · doi:10.1001/jama.2010.785 · Cited by 184
Reanalyses of Randomized Clinical Trial Data
Ebrahim, S., Sohani, Z. N., Montoya, L., Agarwal, A., Thorlund, K., Mills, E. J., & Ioannidis, J. P. A. (2014) · JAMA · doi:10.1001/jama.2014.9646 · Cited by 184
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s004 · Cited by 182
Su, G., Mi, S.-H., Tao, H., Li, Z., Yang, H.-X., Zheng, H., Zhou, Y., & Tian, L. (2013) · Diabetes Care · doi:10.2337/dc12-0925 · Cited by 175
Glucose variability: An emerging target for the treatment of diabetes mellitus
Frontoni, S., Di Bartolo, P., Avogaro, A., Bosi, E., Paolisso, G., & Ceriello, A. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.09.007 · Cited by 174
Penno, G., Solini, A., Bonora, E., Fondelli, C., Orsi, E., Zerbini, G., Morano, S., Cavalot, F., Lamacchia, O., Laviola, L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2264 · Cited by 168
Self-citationLachin, J. M., & Nathan, D. M. (2021) · Diabetes Care · doi:10.2337/dc20-3097 · Cited by 163
“9% of the risk reduction with intensive versus conventional treatment was explained by the group difference in the mean HbA1c levels during the DCCT (4) (Table 1).”
BackgroundSelf-citationTamborlane, W. V., Bode, B. W., Buckingham, B. A., Chase, H. P., Clemons, R. D., Fox, L. A., Gilliam, L. K., Hirsch, I. B., Huang, E. S., Kollman, C., et al. (2008) · Cited by 167
Phenotypes and biomarkers of diabetic retinopathy
Cunha-Vaz, J., Ribeiro, L., & Lobo, C. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.03.003 · Cited by 165
Local and Systemic Inflammatory Biomarkers of Diabetic Retinopathy: An Integrative Approach
Vujosevic, S., & Simó, R. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-21769 · Cited by 165
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s003 · Cited by 162
Journal of Clinical & Cellular Immunology
(2019) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899 · Cited by 163
Glucose variability, HbA1c and microvascular complications
Škrha, J., Šoupal, J., Škrha, J., & Prázný, M. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9347-2 · Cited by 175
“Type 1 diabetes Analysis of the DCCT data showed that, although intensive therapy in patients with Type 1 diabetes reduced the risk of diabetic retinopathy progressing by 73 % compared to standard treatment, high HbA1c levels and longstanding diabetes explained only 11 % of the variation in the risk of retinopathy [36…”
BackgroundMadonna, R., & Caterina, R. D. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.03.005 · Cited by 176
“Taken together, these data show that glucose toxicity exerts a major role in microvascular complications, which are more closely temporally related to the onset of hyperglycemia, than macrovascular ones (Lachin et al., 2008; Nathan et al., 2003; UK Prospective Diabetes Study (UKPDS) Group, 1998a).”
BackgroundElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 249
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc21-s004 · Cited by 154
Frequency of evidence-based screening for retinopathy in type 1 diabetes
The DCCT/EDIC Research Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612836 · Cited by 141
Death during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137
Bergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140
Gerbaud, E., Darier, R., Montaudon, M., Beauvieux, M.-C., Coffin-Boutreux, C., Coste, P., Douard, H., Ouattara, A., & Catargi, B. (2019) · Diabetes Care · doi:10.2337/dc18-2047 · Cited by 138
Hirsch, I. B., Armstrong, D. U., Bergenstal, R. M., Buckingham, B. A., Childs, B. P., Clarke, W. L., Peters, A. L., & Wolpert, H. A. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0016 · Cited by 150
Kassahun, T., Eshetie, T. C., & Gesesew, H. A. (2016) · BMC Research Notes · doi:10.1186/s13104-016-1896-7 · Cited by 170
Duca, L. M., Reboussin, B. A., Pihoker, C., Imperatore, G., Saydah, S., Mayer‐Davis, E. J., Rewers, A., & Dabelea, D. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12809 · Cited by 152
“Specifically, the DCCT study found a 73% risk reduction for progression of retinopathy in the intensive therapy compared with the conventional therapy group, after adjusting for retinopathy level on entry and pre-DCCT level of hyperglycemia.(32) Furthermore, in DCCT, virtually all of the treatment effect on retinopath…”
Monnier, L., Colette, C., Mas, E., Michel, F., Cristol, J., Boegner, C., & Owens, D. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1574-6 · Cited by 136
Artificial intelligence for diabetic retinopathy screening, prediction and management
Gunasekeran, D. V., Ting, D. S. W., Tan, G. S. W., & Wong, T. Y. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000693 · Cited by 158
“…virtue of the fact that diabetes mellitus is a multifactorial complexed disease, our existing methods for predicting the development of diabetic retinopathy are imperfect, whereby glycemic exposure (Glycated haemoglobin and duration of diabetes) only explained Control and Complications Trial [48].”
BackgroundBeisswenger, P. J., Howell, S. K., Russell, G. B., Miller, M. E., Rich, S. S., & Mauer, M. S. (2013) · Diabetes Care · doi:10.2337/dc12-2689 · Cited by 136
Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
Zhou, J. J., Schwenke, D. C., Bahn, G., & Reaven, P. (2018) · Diabetes Care · doi:10.2337/dc18-0548 · Cited by 131
Sartore, G., Chilelli, N. C., Burlina, S., & Lapolla, A. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0459-9 · Cited by 130
“that, although intensive therapy reduced the risk of DR progressing by 73 % compared to standard treatment, high HbA1c levels and longstanding diabetes explained only 11 % of the variation in the risk of retinopathy [6], giving the impression that other factors may contribute to the overall risk of DR progression.”
BackgroundŠoupal, J., Škrha, J., Fajmon, M., Horová, E., Mráz, M., Škrha, J., & Prázný, M. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0205 · Cited by 127
“19,20 GV has been calculated from the standard self-monitored blood glucose (SMBG) data in many studies.”
The Role of HIF1α-PFKFB3 Pathway in Diabetic Retinopathy
Min, J., Zeng, T., Roux, M., Lazar, D., Chen, L., & Tudzarova, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab362 · Cited by 121
Su, W., Chen, S., Huang, Y.-T., Huang, J., Wu, P.-Y., Hsu, W., & Lee, M. (2019) · Nutrients · doi:10.3390/nu11112838 · Cited by 113
Glycemic Variability: Risk Factors, Assessment, and Control
Kovatchev, B. P. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819826111 · Cited by 124
Virk, S. A., Donaghue, K. C., Cho, Y. H., Benitez-Aguirre, P., Hing, S., Pryke, A., Chan, A., & Craig, M. E. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3604 · Cited by 109
Challenges in Elucidating the Genetics of Diabetic Retinopathy
Kuo, J. Z.-C., Wong, T. Y., & Rotter, J. I. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.5024 · Cited by 115
Perreault, L., Pan, Q., Schroeder, E. B., Kalyani, R. R., Bray, G. A., Dagogo-Jack, S. E., White, N. H., Goldberg, R. B., Kahn, S. E., Knowler, W. C., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0244 · Cited by 123
Self-citationGiaccari, A., Sorice, G. P., & Muscogiuri, G. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.018 · Cited by 121
Type 1 diabetes, hyperglycaemia, and the heart
Retnakaran, R. R., & Zinman, B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60767-9 · Cited by 127
Self-citationClinical Implications of Glucose Variability: Chronic Complications of Diabetes
Jung, H. S. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.2.167 · Cited by 110
3. Comprehensive Medical Evaluation and Assessment of Comorbidities
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc17-s006 · Cited by 108
Novel therapeutic targets in diabetic macular edema: Beyond VEGF
Urias, E. A., Urias, G. A., Monickaraj, F., McGuire, P. G., & Das, A. (2017) · Vision Research · doi:10.1016/j.visres.2017.06.015 · Cited by 104
“…revealed that the total glycemic exposure (A1C and duration of diabetes) explains only ∼11% of the variation in retinopathy risk in the complete cohort, so that other factors may presumably explain the remaining 89% of the variation in risk among subjects independent of A1C (Lachin et al., 2008).”
Breton, M. D., Patek, S. D., Lv, D., Schertz, E. M., Robic, J., Pinnata, J., Kollar, L. L., Barnett, C. L., WAKEMAN, C. A., Oliveri, M. C., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0079 · Cited by 103
Genome-wide association study in a Chinese population with diabetic retinopathy
Sheu, W. H., Kuo, J. Z.-C., Lee, I., Hung, Y., Lee, W., Tsai, H.-Y., Wang, J., Goodarzi, M. O., Klein, R., Klein, B. E. K., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt161 · Cited by 99
Hermann, J. M., Hammes, H., Rami-Merhar, B. M., Rosenbauer, J., Schütt, M., Siegel, E. G., Holl, R. W., & on behalf of the DPV Initiative the German BMBF Competence Network Diabetes Mellitus (2014) · PLoS ONE · doi:10.1371/journal.pone.0091137 · Cited by 104
Cavalot, F. L. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12140 · Cited by 110
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
and the DPP Research Group, Nathan, D. M., Bennett, P. H., Crandall, J. P., Edelstein, S. L., Goldberg, R. B., Kahn, S. E., Knowler, W. C., Mather, K. J., Mudaliar, S., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4928-8 · Cited by 91
“[37], studies in which development of diabetes was reduced by 28%, 14% and 58%, respectively (Table 1).”
Self-citationMonnier, L., Colette, C., & Owens, D. R. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.962 · Cited by 89
“concluded that the risk of retinopathy could be explained mainly by the overall glycaemic exposure rather than by glucose variations, which seem to contribute only a small part to these differences [67].”
BackgroundMonnier, L., Colette, C., & Owens, D. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.014 · Cited by 91
Giacco, F., Du, X., Carratù, A. C., Gerfen, G. J., D’Apolito, M., Giardino, I., Rasola, A., Marin, O., Divakaruni, A. S., Murphy, A. N., et al. (2015) · Diabetes · doi:10.2337/db15-0084 · Cited by 92
The Role of Blood Pressure Variability in the Development of Nephropathy in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2010) · Diabetes Care · doi:10.2337/dc10-1000 · Cited by 92
Metadata
- Authors
- Lachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group
- Affiliations
- George Washington University (US)
- Case Western Reserve University (US)
- Harvard University (US)
- Mount Sinai Hospital (CA)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-04-01
- Volume
- 57
- Issue
- 4
- Pages
- 995-1001
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1992103610
- Cited by
- 555
- References
- 13
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 31 · 2023: 31 · 2022: 34 · 2021: 28 · 2020: 31 · 2019: 26 · 2018: 31 · 2017: 31 · 2016: 30 · 2015: 31 · 2014: 36 · 2013: 36 · 2012: 25
- FWCI
- 22.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- NIH Clinical Center
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- glycemic exposure, glycemic variability, postprandial hyperglycemia, microvascular complications, diabetic retinopathy progression, HbA1c, tight glycemic control, Diabetes Control and Complications Trial
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Insulin, Male, Reproducibility of Results, Models, Statistical, Cohort Studies, Biomarkers, Disease Progression, Patient Selection, Racial Groups
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.